This is a preview of subscription content, log in via an institution to check access.
References
Yamada K, Morimoto H, Shimadzu H, et al. Syntheses and structure-activity relationships of sulfonamide derivatives as endothelin antagonists: a potent and selective ET-A antagonist, TA-0201 and related compounds [abstract]. 216th National Meeting of the American Chemical Society. Pt 2. 1998 Aug 23–27; Boston
Hoshino T, Yamauchi R, Kikkawa K, et al. Pharmacological profile of T-0201, a highly potent and orally active endothelin receptor antagonist. J Pharmacol Exp Ther 1998 Aug; 286: 643–9
Ohnishi M, Wada A, Tsutamoto T, et al. Chronic effects of a novel, orally active endothelin receptor antagonist, T-0201, in dogs with congestive heart failure. J Cardiovasc Pharmacol 1998; 31 Suppl. 1: 236–8
Aihara H, Yoneda H, Shimada K, et al. Endothelin-1 blocking action of TA-0201 in the kidney of the anaesthetized dog — comparison with bosentan. Jpn J Pharmacol 1998; 76 Suppl. I: 249
Yamauchi R, Hoshino T, Ban Y, et al. Pharmacological profile of T-0201, a potent nonpeptide endothelin antagonist, and preferable effects in models of pulmonary hypertension induced by monocrotaline. Jpn J Pharmacol 1997; 73 Suppl. I: 75
Yamauti-Kohno R, Miyauchi T, Hoshino T, et al. Beneficial effect of a new endothelin antagonist, TA-0201, on survival and cardiac dysfunction in cardiomyopathic hamsters. Naunyn Schmiedebergs Arch Pharmacol 1998; 358 (2 Suppl. 1): 639
Okada M, Watanabe A, Nagata K, et al. Novel endothelin receptor antagonist T-0201 suppresses neointimal formation of rat carotid artery after balloon angioplasty. Jpn J Pharmacol 1997; 73 Suppl. I: 73
Rights and permissions
About this article
Cite this article
TA 0201. Drugs R&D 2, 33–34 (1999). https://doi.org/10.2165/00126839-199902010-00009
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-199902010-00009